Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

D. Scott Lim, MD, medical director of the Advanced Cardiac Valve Center, and co-director of the Adult Congenital Heart Disease Center at University of Virginia (UVA) Health in Charlottesville, and an associate professor at the University British Columbia, explains how intracardiac echo (ICE) is increasingly being used to help guide structural heart procedures.

Key details on the use of ICE to guide structural heart procedures

Scott Lim, MD, details his experience using intracardiac echo to help guide structural heart procedures with or without traditional TEE. One key benefit of ICE, he explained, is its ability to overcome imaging challenges posed by prior cardiac surgeries.

Heart cardiologists doctors surgery

PCI before TAVR linked to better outcomes than performing both at once

Researchers explored data from more than 50,000 TAVR patients who presented with both severe aortic stenosis and stable coronary artery disease, sharing their findings in JACC: Cardiovascular Interventions.

Medtronic's Evolut Pro TAVR valve treating aortic stenosis

TAVR valve improvements may have helped reduce the impact of paravalvular leak

Multiple studies over the years have linked PVL to an increased risk of adverse outcomes. New research out of Italy, however, suggests that device improvements made by Medtronic, Edwards Lifesciences and Boston Scientific may have reduced PVL's influence.

A study that analyzed patient outcomes in coronary artery bypass grafting (CABG) in veterans showed outcomes for on-pump and off-pump procedures over 10 years to be similar. Photo by Jim Lennon

SAVR/CABG vs. TAVR/PCI: Key differences when heart patients present with severe AS and CAD

Surgery offers multiple long-term benefits when compared to a more interventional approach, though it is still associated with certain risks of its own. In the end, researchers agree, the decision is one that should involve input from surgeons, cardiologists and others.

Gilbert Tang, MD, explains how new transcatheter tricuspid options will help drive surgical volume growth. #TTVR

New transcatheter tricuspid treatment options poised to drive surgical volume growth

Gilbert Tang, MD, explains how transcatheter tricuspid TEER and total valve replacement options will likely lead to higher tricuspid valve surgical volumes in the years ahead.

Newsweek ranked the 50 best heart hospitals in the world

Young SAVR patients live longer with mechanical valves—should surgeons, cardiologists rethink current practice?

Bioprosthetic valves are being used more and more for aortic valve replacement, but mechanical valves appear to provide better long-term outcomes for patients 60 and younger. The new study, based on data from nearly 110,000 patients, was presented at STS 2025 and published in the Journal of the American College of Cardiology.

Cardiologists in Spain encountered an unexpected complication in a 78-year-old transcatheter aortic valve replacement (TAVR) patient, highlighting the experience in JACC: Cardiovascular Interventions.

TAVR valve’s spontaneous leaflet rupture highlights importance of long-term follow-up

Cardiologists believe this is the first time this exact complication has been reported. Even patients who present with no known risk factors, they said, should receive regular follow-up care to ensure such incidents do not go untreated. 

ACC.24 sign American College of Cardiology

American College of Cardiology announces late-breaking clinical trials for ACC.25

The presentations will cover a variety of topics, including coronary artery disease, semaglutide, artificial intelligence, TAVR, heart failure, PCI and much more. ACC.25 takes place March 29-31 in Chicago.

Around the web

GE HealthCare said the price of iodine contrast increased by more than 200% between 2017 to 2023. Will new Chinese tariffs drive costs even higher?

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.